Skip to main content

Table 2 Vaccine characteristics and immunisation strategies considered in the models evaluating routine varicella vaccination

From: Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

Study Age at vaccination Vaccine efficacy Waning (per year) Vaccination coverage Vaccination costs per dose (2010 EUR; German price level)
Banz et al. [35] 15 months; 11–12 years 86 % 0.5 % 85 % (children); 30 % (adolescents) EUR 65.93 (children)a; EUR 71.38 (adolescents)a
Banz et al. [51] 1-2 years; 11–15 years 95 % 0.5 % 70 % (children); 85 % (adolescents) EUR 42.20 (children)a; EUR 56.65 (adolescents)a
Beutels et al. [37] 15 months; 12 years 90 % Waning in 15 % of the protected vaccineesb 70 % EUR 50.82a
Bilcke et al. [30] 1 year (1st dose); 4, 6 or 11 years (2nd dose) Data from van Hoek et al. 2012 Data from van Hoek et al. 2012 50 % or 95 % (1st dose); 50 %, 80 % or 90 % (2nd dose) EUR 44.92a
Bonanni et al. [36] 12-18 months; 13 years 90 % (1st dose); 93 % (2nd dose) 3 % 85 % EUR 46.81a,c
Brisson et al. [31] 12 months; 12 years 93 % 3.1 % 90 % (infants); 80 % (adolescents) EUR 51.42 (children)a; EUR 68.57 (adolescents)a
Brisson et al. [32] Infants; 11 years 93 % 3.1 % 90 % (infants); 80 % (adolescents) EUR 44.32 (children)a; EUR 59.10 (adolescents)a
Coudeville et al. [52] <6 years 90 % Waning in 15 % of the protected vaccineesb 80 % EUR 18.11c,d
Coudeville et al. [53] 12-36 months 97 % 3.1 % 45 %-90 % EUR 52.00a,c
Coudeville et al. [54] 12-36 months 97 % 3.1 % 45 %-90 % EUR 64.08 (Germany)a,c; EUR 59.56 (France)a,c
Diez Domingo et al. [55] 15 months 90 % No waning 95 % EUR 37.11
Getsios et al. [56] 12 months 90 % Waning in 15 % of the protected vaccineesb 85 % EUR 60.25a,d
Ginsberg & Somekh [57] 12 months 87.6 % 3.1 % 94 % EUR 8.01a,c,d
Hammerschmidt et al. [58] 11-23 months (catch-up of 2–17 year olds) 86 % (1-dose schedule); 95 % (2-dose schedule) 0.5 % 90 % (1st dose); 80 % (2nd dose); 30 % (catch-up); 10 % (comparator) EUR 47.38 (monovalent vaccine); EUR 47.92 (varicella-attributable cost of the MMRV vaccine)
Huse et al. [59] 15 months 95 % No waning Not specified EUR 62.31a
Lenne et al. [60] 1-2 years 97 % 3,1 % 97,15 % EUR 42.54a
Lieu et al. [61] <6 years 90 % Waning in 15 % of the protected vaccineesb 97 % EUR 54.12a
Preblud et al. [62] 15 months 90 % No waning 90 % EUR 25.53
Scuffham et al. [63] 15 months 95 % No waning 80 %; 10 % (comparator) EUR 45.94
Scuffham et al. [34] 12 months; 12 years 95 % No waning 80 % (infants); 50-75 % (adolescents) EUR 42.26
Thiry et al. [64] 11 years 93,12 % 3.1 % 60 % EUR 52.36a
van Hoek et al. [33] 1 year (1st dose); 3 years (2nd dose) 89-96 % (1st dose); 93-96 % (2nd dose) 1.5-6.7 % (1st dose); 0.05-2.6 % (2nd dose) 90 % (1st dose); 80 % (2nd dose) EUR 41.19
Zhou et al. [29] Children 80 % (1-dose schedule)e; 93 % (2-dose schedule) No waning Age-specific coverage rates; 95 % (2nd dose) EUR 49.90 (monovalent vaccine)f; EUR 65.64 (MMRV vaccine)f
  1. MMRV measles, mumps, rubella and varicella
  2. aIncluding administration costs
  3. bWaning rate per year not quantified
  4. cIncluding costs of treating adverse events
  5. dIncluding vaccine wastage
  6. eThis efficacy estimate was not directly used in the model; the vaccine-induced reduction in incidence was calculated by using age-specific surveillance data
  7. fPublic sector price
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us